CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Imatinib mesylatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00684411
NCT00684411Phase 2Completed
CompareCT.gov

A Pilot Study of Gleevec (Imatinib Mesylate) in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

Dana-Farber Cancer Institute·interventional·Posted May 26, 2008·Updated Jan 5, 2017

In Brief

A Phase 2 clinical trial evaluating Imatinib mesylate for T Cell Non-Hodgkin Lymphoma. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this research study is to evaluate the overall response rate to imatinib mesylate in participants with relapsed or refractory T cell non-Hodgkin's lymphoma. This drug has been used in chronic myeloid leukemia and information from those other research studies suggests that it may help to treat T cell non-Hodgkin's lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsT Cell Non-Hodgkin Lymphoma
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Novartis

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 26, 2008
Enrollment StartJun 1, 2008
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.1 years ago

Interventions

Imatinib mesylatedrug